Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
2.
Blood Research ; : 23-30, 2016.
Artículo en Inglés | WPRIM | ID: wpr-23502

RESUMEN

BACKGROUND: Plasma cell leukemia (PCL) is a rare and aggressive plasma cell neoplasm. In PCL, clonal plasma cells comprise ≥20% of the peripheral blood (PB) leukocytes and/or the absolute clonal PB plasma cell count is ≥2×10(9)/L. Primary PCL (PPCL) originates de novo, whereas, secondary PCL (SPCL) evolves from pre-existing multiple myeloma. METHODS: Clinicohematological features, immunophenotypic profile, and survival of PCL patients were analyzed retrospectively. RESULTS: Between January 2007 and December 2014, ten PPCL and four SPCL patients were investigated (8 PPCLs and 3 SPCLs had complete clinical data). All were North Indians, sharing common geography and ethnicity. Our cohort showed less frequent renal failure, more frequent hepatomegaly, and non-secretory type disease. In contrast to western literature, flow cytometric immunophenotyping of our cohort revealed altered expression of CD138 (67%), CD56 (33%), and CD20 (0%). With novel therapeutic agents, these PPCL patients had a median overall survival of 15 months. CONCLUSION: We highlight that our PPCL patients from North India had distinct clinicohematological and immunophenotypic profiles. The significance of our findings must be tested in a larger patient cohort and must be supported by molecular and cytogenetic investigations to unmask possible significant effects on pathogenesis.


Asunto(s)
Humanos , Estudios de Cohortes , Citogenética , Geografía , Hepatomegalia , Inmunofenotipificación , India , Leucemia de Células Plasmáticas , Leucocitos , Mieloma Múltiple , Neoplasias de Células Plasmáticas , Células Plasmáticas , Plasma , Insuficiencia Renal , Estudios Retrospectivos , Centros de Atención Terciaria , Atención Terciaria de Salud
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA